Evidence map›Paper›PMID 34289449›Full record

ArticleAging2021

Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.

Jingjing Wu, Wen Xu, Lina Ma, Jiayu Sheng, Meina Ye, Hao Chen, Yuzhu Zhang, Bing Wang, Mingjuan Liao, Tian Meng and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Roles of AFAP1-AS1 in Gynecology and Urogenital System.Current pharmaceutical design · 2024
    Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Biomolecules · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Interplay between LncRNAs and microRNAs in Breast Cancer.International journal of molecular sciences · 2023
    Review
  14. Review
  15. Metformin and long non-coding RNAs in breast cancer.Journal of translational medicine · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jingjing WuDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Wen XuState Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Lina MaDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Jiayu ShengDepartment of Breast Surgery, Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Meina YeDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Hao ChenDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Yuzhu ZhangDepartment of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China.
Bing WangDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Mingjuan LiaoDepartment of Traditional Chinese Medicine, The Ninth People's Hospital, Medical School of Shanghai Jiaotong University, Shanghai, China.
Tian MengDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Yue ZhouDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Hongfeng ChenDepartment of Breast, Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
Shanghai University of Traditional Chinese Medicine · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNEast China University of Science and Technology · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNShanghai Ninth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This investigation attempted to discern whether formononetin restrained progression of triple-negative breast cancer (TNBC) by blocking lncRNA AFAP1-AS1-miR-195/miR-545 axis. We prepared TNBC cell lines (i.e. MDA-MB-231 and BT-549) and normal human mammary epithelial cell line (i.e. MCF-10A) in advance, and the TNBC cell lines were, respectively, transfected by pcDNA3.1-lncRNA AFAP1-AS1, si-lncRNA AFAP1-AS1, pcDNA6.2/GW/EmGFP-miR-545 or pcDNA6.2/GW/EmGFP-miR-195. Resistance of TNBC cells in response to 5-Fu, adriamycin, paclitaxel and cisplatin was evaluated through MTT assay, while potentials of TNBC cells in proliferation, migration and invasion were assessed via CCK8 assay and Transwell assay. Consequently, silencing of lncRNA AFAP1-AS1 impaired chemo-resistance, proliferation, migration and invasion of TNBC cells (

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansIsoflavonesMiceMice, Inbred BALB CMicroRNAsRNA, Long NoncodingTriple Negative Breast NeoplasmsAntineoplastic AgentsformononetinIsoflavonesMicroRNAsMIR545 microRNA, humanMIRN195 microRNA, humanRNA, Long Noncodingchemo-resistanceformononetinlncRNA AFAP1-AS1miR-195/miR-545triple-negative breast cancer

Identifiers

PMID34289449
PMCPMC8351708
OpenAlexW3183234149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.